

How machine translation can dramatically accelerate clinical trial progression

Help is at hand for clinical research teams swamped by documentation, coming, perhaps surprisingly, in the form of AI-powered translations.

You run clinical trials to test the safety and effectiveness of new treatments, not to manage huge volumes of documentation. Yet when trials advance to phase 2 and beyond, the time spent just on manually reviewing records for participation eligibility, for example, can become a severe speed bump on the road to your trial progression and success.

What's more, when the number of participants is large, the chance of them all speaking the same language as your researchers is small. This is especially true with the increasing geographic disparity of modern trials. As such, securely translating confidential patient data slows down the trial further, while adding to its administrative cost.


The need to automate, but also its limitations

How then—in a life sciences industry clamouring for ever faster time-to-value—can your principal investigators hope to get the requisite number of patients onto a trial faster, without error, and cost-effectively?

The solution lies in automating much of the documentation stages. For example, through the implementation of automated patient screening algorithms. These quickly and securely analyze patient records, and identify suitable candidates based on predefined criteria, saving you huge amounts of time when compared to current human methods.

Yet this level of automation will only get researchers so far, because as noted, translation of at least some patients' records is virtually inevitable in a medium-large sample group. Automation tools provide optimal value when they are used universally, meaning the integration of AI-powered machine translation (MT) tools is a must not only from an efficiency standpoint but also from a cost-effectiveness one.

MT can instantly translate huge volumes of documentation into multiple languages. It ensures all participants can understand and engage with your trial materials, and that your researchers can be assured of patient eligibility thanks to MT's extremely high accuracy.



Does this mean the machines have taken over?

It's important to note that MT is not a wholesale replacement for human translators. Rather, think of it as a tool that assists in the speed of translation, helping your clinical teams reach the point at which they can make an impact through their work sooner. Human review and validation should remain a key part of your translation workflows to ensure accuracy and maintain compliance with regulatory standards.

Language Weaver is a great example of a leading MT solution that can rapidly speed up your clinical team's documentation and review processes. Secure-by-design, it seamlessly integrates the ability to translate over [3,000 language combinations into your organization's existing workflows.](#)

Language Weaver's adaptive capabilities means it learns industry-specific terminology, nuance, and linguistic intricacies with every use, so it is able to continually improve its accuracy and relevance. With multiple deployment options available, it is also infinitely scalable, with a translation capacity of 100,000s+ words per minute. With security that never compromises patient data security or confidentiality, it's an essential tool for any globally-minded organization running clinical trials.

Discover the potential of implementing Language Weaver across your entire operations, and how it can rapidly accelerate your teams' time to impact by visiting our dedicated landing page.

[languageweaver.com/life-sciences](https://www.languageweaver.com/life-sciences)

About RWS

RWS Holdings plc is a unique, world-leading provider of technology-enabled language, content and intellectual property services. Through content transformation and multilingual data analysis, our combination of AI-enabled technology and human expertise helps our clients to grow by ensuring they are understood anywhere, in any language.

Our purpose is unlocking global understanding. By combining cultural understanding, client understanding and technical understanding, our services and technology assist our clients to acquire and retain customers, deliver engaging user experiences, maintain compliance and gain actionable insights into their data and content.

Over the past 20 years we've been evolving our own AI solutions as well as helping clients to explore, build and use multilingual AI applications. With 45+ AI-related patents and more than 100 peer-reviewed papers, we have the experience and expertise to support clients on their AI journey.

We work with over 80% of the world's top 100 brands, more than three-quarters of Fortune's 20 'Most Admired Companies' and almost all of the top pharmaceutical companies, investment banks, law firms and patent filers. Our client base spans Europe, Asia Pacific, Africa and North and South America. Our 65+ global locations across five continents service clients in the automotive, chemical, financial, legal, medical, pharmaceutical, technology and telecommunications sectors.

Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).

For further information, please visit: www.rws.com

© 2024 All rights reserved. Information contained herein is deemed confidential and the proprietary information of RWS Group*.

*RWS Group shall mean RWS Holdings plc for and on behalf of its affiliates and subsidiaries.

